美罗培南联合乌司他丁治疗细菌性脓毒血症及对血清降钙素原与炎症因子的影响  

Effect of meropenem combined with ulinastatin on bacterial sepsis and on serum procalcitonin and inflammatory factors

作　　者：吴晓鹏[1] 张金花[1] 张彬 WU Xiaopeng;ZHANG Jinhua;ZHANG Bin(Department of Clinical Pharmacy,Department of Pharmacy,Songgang People′s Hospital Bao′an District of Shenzhen,Shenzhen 518105,China)

机构地区：[1]深圳市宝安区松岗人民医院药剂科临床药学室

出　　处：《西北药学杂志》2019年第6期814-818,共5页Northwest Pharmaceutical Journal

摘　　要：目的分析美罗培南联合乌司他丁治疗细菌性脓毒血症患者的疗效及对血清降钙素原(PCT)与炎症因子的影响。方法127例细菌性脓毒血症患者按随机数字表法分为对照组(67例)和研究组(60例),对照组采用美罗培南治疗,研究组在美罗培南的基础上联合乌司他丁治疗。比较2组的临床疗效、细菌清除率、血清PCT及炎症因子、血常规、体温、急性生理与慢性健康评分(APACHE-Ⅱ评分)、不良反应发生情况及预后情况。结果研究组总有效率及细菌清除率均高于对照组,差异有统计学意义(P<0.05)。治疗前,2组血清PCT及炎症因子水平比较差异无统计学意义;治疗后,2组血清PCT及炎症因子水平均下降,研究组低于对照组。研究组血常规、体温和APACHE-Ⅱ评分均低于对照组(P<0.05)。2组不良反应发生率比较差异无统计学意义。研究组病死率低于对照组(P<0.05)。结论美罗培南联合乌司他丁治疗细菌性脓毒血症患者的疗效优于美罗培南,能够降低血清PCT及炎症因子水平,降低病死率,且用药安全性高。Objective To analyze the effect meropenem combined with ulinastatin in the treatment of bacterial sepsis and its effect on serum procalcitonin(PCT)and inflammatory factors.Methods 127 patients with bacterial sepsis were randomly divided into control group(67 cases)and study group(60 cases).The control group were treated with meropenem and the study group were treated with ulinastatin on the basis of meropenem.The clinical efficacy,bacterial clearance rate,serum PCT and inflammatory factors,blood routine,body temperature,acute physiology and chronic health score(APACHE-Ⅱscore),adverse reactions and prognosis were compared between the 2 groups.Results The total effective rate and bacterial clearance rate of the study group were higher than those of the control group with statistical difference(P<0.05).Before treatment,there was no difference in serum PCT and inflammatory factors between the 2 groups.After treatment,the levels of serum PCT and inflammatory factors in both groups decreased,while those in the study group were lower than those in the control group.The blood routine test,body temperature and APACHE-Ⅱscore in the study group were lower than those in the control group(P<0.05).There was no difference in the incidence of adverse reactions between the 2 groups.The mortality of the study group was lower than that of the control group(P<0.05).Conclusion Meropenem combined with ulinastatin is better than meropenem in the treatment of bacterial sepsis.It can reduce the levels of PCT and inflammatory factors in serum,reduce the mortality rate,and has high safety.

关 键 词：美罗培南 乌司他丁 细菌性脓毒血症 降钙素原 炎症因子 

分 类 号：R978[医药卫生—药品]